An observational study in Acute Respiratory Infection and Acute Respiratory Tract Infection, sponsored by European Clinical Research Alliance for Infectious Diseases (ECRAID). Recruiting at 27 sites in 10 countries. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by European Clinical Research Alliance for Infectious Diseases (ECRAID) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Acute respiratory infections (ARI) are one of the most frequent reasons for hospital admission and antibiotic use, and can be caused by a broad range of pathogens, including respiratory viruses with proven epidemic potential, e.g. influenza and coronaviruses. The POS-ARI-ER study will focus on describing the different routine diagnostic and therapeutic practices in the work-up and treatment of ARI, as well as clinical outcomes across the patient population. In addition, POS-ARI-ER aims to characterise both the adult and paediatric patient populations with ARI presenting to acute hospital settings in Europe, and the aetiology of ARI in these patients.
The POS-ARI-ER study is a perpetual, observational study (POS), designed to provide data for clinical characterisation of acute respiratory infections (ARIs) in adults presenting to hospital settings across Europe.
Establishing the etiological cause of ARI at the time of presentation is difficult with currently available diagnostic approaches. Improvements in diagnosis and strategies for use of targeted antibiotic and antiviral treatment strategies are needed to improve patient outcomes, and to reduce selection of antimicrobial resistance (AMR) and antiviral resistance. Recent advances in routine diagnostics in secondary care settings include molecular tests that can detect multiple pathogens simultaneously, and highly sensitive and specific point of care tests that can provide attending clinicians with rapid results. However, the implementation of these technologies into routine clinical practice within hospitals, and any impact on treatment decisions or patient outcomes, has not been widely evaluated.
The aim is to accurately characterise cases of ARIs presenting to acute hospital services, such as emergency departments and acute medical assessment units, in Europe.
Characterisation will focus on identifying the routine diagnostic methods (laboratory and point of care testing) and pharmacological interventions employed by different centres in patients presenting with ARI. Data will be collected using standardised report forms that capture clinical, laboratory and prescribing information. Participants will include those who require admission to hospital, as well as patients who are discharged the same day from the emergency department or acute medical assessment unit. In addition, a subset of participants will have single upper respiratory tract research sample (e.g. nose/throat swab) obtained at enrolment (within 24 hours), for pathogen detection by molecular methods.
Describing the variations in routine practice provides a foundation both to improve patient care through currently available approaches, as well as to inform areas of focus for development of new strategies.
2,097 studies on the registry are indexed under Infections; 361 are open to participants now.
This study's planned enrollment of 11,750 is above the median of 300 across 688 observational studies indexed under Infections.
Browse Infections studies →European Clinical Research Alliance for Infectious Diseases (ECRAID) is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 29, 2026. See what changed
Group 1: Adults (≥ 18 years old) presenting to acute hospital services with suspected community-acquired acute respiratory tract infection Group 2: Infants, children and adolescents (\< 18 years old) presenting to acute hospital services with suspected community-acquired acute respiratory tract infection
Inclusion Criteria:
Inclusion criterion for Group 1:
Inclusion criterion for Group 2:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults ≥ 18 years old
Other: Data collection
Infants, children and adolescents \< 18 years old
Other: Data collection
Data collection from study participants to characterise diagnostic and therapeutic practices.
Proportion of adult patients undergoing ARI-relevant microbiology and virology investigations.
Calculate the proportion of types of ARI-relevant microbiology and virology investigations performed.
Time frame: Five years
Proportion of adult patients receiving antibiotics, antivirals, antifungals and/or immunomodulators.
Calculate the proportion of cases receiving antibiotics, antivirals, antifungals and/or immunomodulators.
Time frame: Five years
Clinical outcome of adults with community acquired ARI in acute hospital settings in Europe.
Maximal score using the ordinal scale assessed at discharge, death or at 28 days after hospital admission: 6= death, 5= hospitalisation requiring extracorporeal membrane oxygenation (ECMO) and/or invasive mechanical ventilation, 4= hospitalisation requiring non invasive ventilation (NIV) and/or high flow nasal cannula (HFNC) oxygen therapy, 3= requiring supplemental oxygen (but not NIV/HFNC), 2= hospitalisation not requiring supplemental oxygen, 1= not hospitalised.
Time frame: Last day in hospital, at death or 28 days after admission, whichever comes first.
Length of hospital and/or ICU stay in adults with community acquired ARI in acute hospital settings in Europe.
Number of days patient admitted to hospital or ICU.
Time frame: Last day in hospital, at death or 28 days after admission, whichever comes first.
Duration of NIV and IMV/ECMO in adults with community acquired ARI in acute hospital settings in Europe.
Number of days patients receiving NIV and IMV/ECMO.
Time frame: Last day in hospital, at death or 28 days after admission, whichever comes first.
All cause mortality in adults with community acquired ARI in acute hospital settings in Europe.
Total number of deaths for each ARI-related pathogen.
Time frame: Last day in hospital, at death or 28 days after admission, whichever comes first.
Patient demographics of the adult patient population with ARI presenting to acute hospital settings in Europe.
Evaluate demographics of patient population with ARI.
Time frame: Five years
Comorbidities in the adult patient population with ARI presenting to acute hospital settings in Europe.
Evaluation of comorbidities in patient population with ARI.
Time frame: Five years
Presenting symptoms in the adult patient population with ARI presenting to acute hospital settings in Europe.
Evaluation of presenting symptoms in the adult patient population with ARI.
Time frame: Five years
Physiological measurements in the adult patient population with ARI presenting to acute hospital settings in Europe.
Evaluation of the physiological measurements in the adult patient population with ARI.
Time frame: Five years
Aetiology of ARI in adults presenting to acute hospital settings in Europe.
Detection of putative pathogens in respiratory tract samples (research upper respiratory tract sample at presentation and ARI-relevant microbiology/virology results obtained through routine clinical care).
Time frame: Five years
Association between clinical outcomes and diagnostic or treatment related variables, for different aetiologies of community acquired ARI in adults presenting to hospital across Europe.
Maximal score on ordinal scale assessed at discharge, death or at 28 days after hospital admission: 6= death, 5= hospitalisation requiring extracorporeal membrane oxygenation (ECMO) and/or invasive mechanical ventilation, 4= hospitalisation requiring non invasive ventilation (NIV) and/or high flow nasal cannula (HFNC) oxygen therapy, 3= requiring supplemental oxygen (but not NIV/HFNC), 2= hospitalisation not requiring supplemental oxygen, 1= not hospitalised, stratified by pathogen.
Time frame: Last day in hospital, at death or 28 days after admission, whichever comes first.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Feb 2027, 44 months after the start.
Of 262 non-industry observational studies under Infections, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 79. This study's planned 44 months is above that.
Counting every sponsor, half of 300 studies reached it within 35 months; a quarter within 18 and three quarters within 67.
Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Feb 2026 → Feb 2027 and completion Feb 2026 → Feb 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
European Clinical Research Alliance for Infectious Diseases (ECRAID)